Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting
18 June 2021 - 9:35PM
Diffusion Pharmaceuticals Inc. (NASDAQ:
DFFN) (“Diffusion,” “we” or the “Company”), an
innovative biopharmaceutical company developing novel therapies
that enhance the body’s ability to deliver oxygen to areas where it
is needed most, reminds stockholders to vote on the proposals
listed in the Company’s proxy statement in advance of its upcoming
annual meeting.
Stockholders of record on May 5, 2021 should
have previously received proxy materials in connection with
Diffusion’s 2021 Annual Meeting of Stockholders to be held Friday,
June 25, 2021, at 1:00 p.m. EDT (“Annual Meeting”). As set forth in
the proxy materials, the Annual Meeting will be conducted as a
virtual meeting hosted via a live webcast. Stockholders will be
able to listen, vote, and submit questions from any location with
internet connectivity. Stockholders or their proxy holder will be
able to attend the Annual Meeting online, vote, and submit
questions by following the instructions provided in their Notice
Regarding the Availability of Proxy Materials and proxy
statement.
We believe the vote of each of our stockholders
is important. Whether shares are held directly as a stockholder of
record or beneficially in “street name” (through a broker, bank, or
other nominee), stockholders may vote their shares without
attending the Annual Meeting, by granting a proxy, or, for shares
held in street name, by submitting voting instructions to your
broker or nominee. Instructions for voting shares through each of
the foregoing methods are included in the Company’s proxy materials
and are summarized below.
The Board of Directors and management of
Diffusion Pharmaceuticals Inc. appreciate the support and thanks
its stockholders for their investment in Diffusion
Pharmaceuticals.
2021 Annual Meeting of
Stockholders
The 2021 Annual Meeting of Stockholders of
Diffusion Pharmaceuticals, Inc. will be held Friday, June 25, 2021,
at 1:00 p.m., ET, virtually via the internet at
www.meetingcenter.io/204775050; the password for the meeting is
DFFN2021. To access the
virtual meeting, stockholders must have the information printed in
the proxy materials. To vote your shares, stockholders
must go online or request a paper copy of the proxy materials to
receive a proxy card. Further information can be found in the proxy
materials filed with the SEC on April 30, 2021, which can be
accessed via
https://investors.diffusionpharma.com/sec-filings/sec-filings.
Stockholders may also submit questions prior to
the date of the Annual Meeting by e-mailing them
to proxyrequests@diffusionpharma.com.
If I was a Diffusion stockholder as of
the record date, how do I vote my shares?
If you are a registered
stockholder (i.e., you hold your shares through our
transfer agent, Computershare), you do not need to register to
attend the Annual Meeting virtually. As the stockholder whose
shares are registered in your name, you may vote your shares by one
of the following methods:
- Virtually, by
joining the Annual Meeting and following the voting instructions
available on the meeting portal during the meeting.
- Vote by Internet,
by going to the web address
http://www.envisionreports.com/DFFN and following the
instructions for Internet voting shown on your proxy card.
- Vote by Telephone,
by dialing 1-800-652-8683 and following the instructions
for telephone voting shown on your proxy
card.
If you hold your shares through an
intermediary, such as a bank or broker, you must register in
advance using the instructions below.
- To register to attend the Annual
Meeting online by webcast you must submit proof of your proxy power
(legal proxy) reflecting your holdings along with your name and
email address to Computershare. Requests for registration must be
labeled as “Legal Proxy” and be received no later than 5:00 p.m.,
Eastern Time, on June 22, 2021.
- You will receive a confirmation of
your registration by e-mail after Computershare receives your
registration materials.
- Requests for registration should be
directed to Computer through the following means:
- By email : Forward the email from
your broker, or attach an image of your legal proxy, to
legalproxy@computershare.com
About Diffusion Pharmaceuticals
Inc.Diffusion Pharmaceuticals Inc. is an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most. Diffusion’s lead product candidate, TSC, is being developed
to enhance the diffusion of oxygen to tissues with low oxygen
levels, also known as hypoxia, a serious complication of many of
medicine’s most intractable and difficult-to-treat conditions. In
addition to TSC, Diffusion’s product candidate DFN-529, a novel,
allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage
development. For more information, please visit us at
www.diffusionpharma.com.
Forward-Looking StatementsThis
press release includes express and implied forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including regarding the Company’s
upcoming annual meeting of stockholders. The Company may, in some
cases, use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately,” or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Although the Company believes that it has a reasonable
basis for each forward-looking statement contained herein,
forward-looking statements by their nature involve risks and
uncertainties, known and unknown, many of which are beyond the
Company’s control, and as a result the Company’s actual results
could differ materially from those expressed or implied in any
forward-looking statement. Particular risk and uncertainties
include, among other things, those related to: the Company’s
ability to obtain a quorum of holders sufficient to properly
convene its annual meeting of stockholders under its bylaws;
general economic, political, business, industry, and market
conditions, including the ongoing COVID-19 pandemic; and the other
factors discussed under the heading “Risk Factors” in the Company’s
filings most recent Annual Report on Form 10-K and other filings
with the U.S. Securities and Exchange Commission. Any
forward-looking statements in this press release speak only as of
the date hereof (or such earlier date as may be identified) and,
except as required by applicable law, rule, or regulation, the
Company undertakes no obligation to update any such statements
after the date hereof.
ContactsInvestors: Tiberend
Strategic Advisors, Inc. Maureen McEnroe, CFA/Lisa
Shermmcenroe@tiberend.com / lsher@tiberend.com
Media: Kate
BarretteRooneyPartners (212)
223-0561Kbarrette@rooneyco.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2024 to May 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From May 2023 to May 2024